natgillin/translations-raw huggingface dataset:
In healthy subjects, the absorption of ospemifene is not affected by co-administration of oral omeprazole, a medicinal product that increases gastric pH.
Pri zdravih osebah sočasna uporaba peroralnega omeprazola, zdravila, ki povečuje pH v želodcu, ne vpliva na absorpcijo ospemifena
CYP2C9 poor metabolisers
Bolnice s slabo presnovo s CYP2C9
Hepatic impairment
- glavobol
In vitro, ospemifene and 4-hydroxyospemifene inhibited glucuronidation via UGT1A3 and UGT1A9 at clinically relevant concentrations.
Ospemifen in 4-hidroksiospemifen sta in vitro zavrla glukoronidacijo prek UGT1A3 in UGT1A9 v klinično pomembnih koncentracijah.
Dyspareunia 60 mg OSP Placebo p-value 60 mg OSP Placebo p-value
60 mg OSP Placebo vrednost p 60 mg OSP Placebo vrednost p Preskušanje 1 -1,26
Therefore care should be taken if ospemifene is administered with a BCRP inhibitor.
Zato je pri sočasni uporabi ospemifena z zaviralcem BCRP potrebna previdnost.
In patients with moderate hepatic impairment the exposure of ospemifene and 4-hydroxyospemifene was approximately 30% and 70% higher.
4-hidroksiospemifenu približno 30% oz. 70% višja.
- If you are allergic to ospemifene or any of the other ingredients of this medicine (listed in section 6).
Kaj morate vedeti, preden boste vzeli zdravilo Senshio Ne jemljite zdravila Senshio - če ste alergični na ospemifen ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Contains lactose.
povezanih z dojkami.
Trial 1 Trial 2
Preskušanje 1
Fri.
Disparevnija
Across all placebo-controlled clinical trials of ospemifene, deep vein thrombosis occurred at a frequency of approximately 3.65 cases per 1,000 patient years on 60 mg ospemifene (95% confidence interval of 0.44 to 13.19) versus 3.66 cases per 1,000 patient years for placebo (95% confidence interval of 0.09 to 20.41; relative risk is 1.0).
(95-% interval zaupanja 0,44 do 13,19) v primerjavi s 3,66 primerov na 1.000 bolnic-let za placebo
Coadministration of ospemifene with strong/moderate CYP3A4 inhibitors should be avoided in patients who are known or suspected to be CYP2C9 poor metabolizers based on genotyping or previous history/experience with other CYP2C9 substrates.
pri bolnicah, za katere je znano ali pri se sumi, da imajo slabo presnovo s CYP2C9 na podlagi genotipiziranja ali z obstoječo anamnezo/izkušnjami z drugimi substrati CYP2C9, izogniti.
Any other medicine belonging to the group called SERMs, such as tamoxifen, toremifene, bazedoxifene and raloxifene.
• Vsa druga zdravila, ki sodijo v skupino zdravil, imenovanih SERM, kot so tamoksifen,
Co-administration of ketoconazole, a strong CYP3A4 inhibitor, increased the AUC of ospemifene by 1.4-fold.
močnega zaviralca CYP3A4, je povečala AUC ospemifena za 1,4-krat.
It must not be taken by women who are pregnant, who could still have a baby or are breast-feeding.
Nosečnice, ženske v rodni dobi ali ženske, ki dojijo, ga ne smejo uporabljati.
No clinically meaningful differences in ospemifene pharmacokinetics have been observed over the age range studied (40-80) years of age.
V razponu preučevane starosti (40-80) niso opazili klinično pomembnih razlik v farmakokinetiki ospemifena.
Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy.
(VVA, vulvar and vaginal atrophy) pri ženskah po menopavzi, ki niso primerne za lokalno vaginalno zdravljenje z estrogenom.
Oudehaske
Oudehaske Nizozemska
The MAH shall complete, within the stated timeframe, the below measures:
Obveznost izvedbe ukrepov po pridobitvi dovoljenja za promet Imetnik dovoljenja za promet z zdravilom mora v določenem časovnem okviru izvesti naslednje ukrepe:
Gender Senshio is indicated for use only in postmenopausal women.
Zdravilo Senshio je indicirano samo pri ženskah po menopavzi.
No dose adjustment is necessary in patients with mild or moderate hepatic impairment.
Pri bolnicah z blago ali zmerno okvaro jeter odmerka ni treba prilagajati.
Patients with liver disease
Žilne bolezni vročinski oblivi
How to store Senshio
Shranjevanje zdravila Senshio
Both CYP2C9 and CYP3A4 are involved in the metabolism of ospemifene.
Pri presnovi ospemifena sodelujeta tako CYP2C9 kot CYP3A4.
Ospemifene was not mutagenic or clastogenic when evaluated in a standard battery of in vitro and in vivo tests.
V standardnem nizu testov in vitro in in vivo ospemifen ni bil mutagen ali klastogen.
- Headache - Vaginal bleeding
izcedek iz spolovil, vaginalna krvavitev hipertrofija endometrijaa
Ospemifene and its major metabolite, 4-hydroxyospemifene, are metabolised by multiple metabolic pathways, the main enzymes involved are UGT1A3, UGT2B7, UGT1A1 and UGT1A8, and CYP2C9,
pri čemer so glavni encimi, ki so vključeni v presnovo UGT1A3, UGT2B7, UGT1A1 in UGT1A8 ter CYP2C9, CYP3A4 in CYP2C19.
C.
PC
No dose adjustment is necessary for patients with mild to moderate hepatic impairment.
Jetrna okvara Pri bolnicah z blago do zmerno jetrno okvaro odmerka ni treba prilagajati.
Contents of the pack and other information What Senshio contains
Kaj vsebuje navodilo Kaj je zdravilo Senshio in za kaj ga uporabljamo
No changes in blood biochemical parameters such as ALT or ALP were determined in postmenopausal women treated with Ospemifene in clinical studies.
Pri ženskah po menopavzi, ki so se v kliničnih študijah zdravile z ospemifenom, niso opazili sprememb biokemičnih parametrov v krvi, kot sta vrednost ALT
The PL is updated in accordance.
V skladu s tem se posodobi tudi navodilo za uporabo zdravila.
Talk to your doctor before taking Senshio with:
Pred začetkom jemanja zdravila Senshio s katerim od naslednjih zdravil se posvetujte z zdravnikom:
Close monitoring is required with frequent or prolonged use.
Skrbno spremljanje je potrebno pri pogosti ali daljši uporabi.
Date of first Authorisation: 25 November 2008 Date of latest renewal: 26 August 2013
Datum prve odobritve: 25. november 2008 Datum zadnjega podaljšanja: 26. avgust 2013
2, cold hands and feet
2, hladne dlani in stopala
However, a risk to the suckling child cannot be excluded.
Vendar pa tveganja za dojenčka ne moremo izključiti.
It may harm them even if their signs of illnesses are the same as yours.
Njim bi lahko celo škodovalo, čeprav imajo znake bolezni, podobne vašim.
These could be the signs of an allergic reaction (frequency is not known).
To so lahko znaki alergijske reakcije (pogostnost ni znana).
How to use
Kako uporabljati
B-2870 Puurs Belgium or
B-2870 Puurs Belgija ali
Do not put in any more drops until it is time for your next regular dose.
Kapljic ne vkapajte ponovno, dokler ne bo čas za naslednji redni odmerek.
4 weeks after first opening.
4 tedne po prvem odprtju
They are classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000), or not known (cannot be estimated from the available data).
Razvrščeni so v skladu z naslednjim dogovorom: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1000), zelo redki (<1/10.000) ali pogostnost neznana (je ni mogoče oceniti iz razpoložljivih podatkov).
Not known (frequency cannot be estimated from the available data)
Neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti):
Contact with soft contact lenses should be avoided.
Stiku z mehkimi kontaktnimi lečami se je treba izogibati.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določenie v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7) Direktive 2001/83/ES, in vseh kasnejših posodobitvah, objavljenih na evropskem spletnem portalu o zdravilih.
(see section 4.4 Special warnings and precautions for use), keratopathy
(glejte poglavje 4.4 Posebna opozorila in previdnostni ukrepi), keratopatija
Cartons containing 1 or 3 bottles.
Škatle z 1 ali 3 kapalnimi vsebniki.
You can usually carry on taking the drops, unless the effects are serious.
Običajno lahko nadaljujete z uporabo kapljic kljub neželenim učinkom, razen če so resni.
Throw away the bottle 4 weeks after first opening to prevent infections, and use a new bottle.
Kapalni vsebnik zavrzite 4 tedne po prvem odprtju, da boste preprečili okužbe, in potem uporabite nov vsebnik.
(predominantly in patients with preexisting bronchospastic disease), dyspnoea
(predvsem pri bolnikih z obstoječo bronhospastično boleznijo), dispneja
The following measure is useful to limit the amount of medicine that will come into the blood after application of eye drops: - Keep the eyelid closed, while simultaneously applying gentle pressure to the corner of the eye next to the nose with a finger for at least 2 minutes.
Naslednji ukrepi pomagajo zmanjšati količino zdravila, ki bo prišla v kri po uporabi kapljic za oko: - Držite očesno veko zaprto, medtem ko sočasno s prstom nežno pritiskate na očesni kot ob nosu vsaj 2 minuti.
This medicine contains 3.34 µg benzalkonium chloride per drop (= 1 dose) which is equivalent to 0.01% or 0.1 mg/ml.
To zdravilo vsebuje 3,34 µg benzalkonijevega klorida na kapljico (= 1 odmerek), kar je enako 0,01 % ali 0,1 mg/ml.
White to off-white uniform suspension, pH 7.2 (approximately).
Bela do belkasta, enakomerna suspenzija, pH 7,2 (približno).
Clinical effects:
Klinični učinki:
The response of these patients should be closely observed.
Odziv teh bolnikov na zdravljenje je torej treba skrbno spremljati.
3, nightmare
3, nočne more
Caution is recommended in the concomitant use of this medicinal product with clonidine.
Previdnost je potrebna pri sočasni uporabi tega zdravila s klonidinom.
Stop using this medicine and contact your doctor immediately if you develop skin rash, severe skin reaction, or severe redness and itching of the eye.
Prenehajte z uporabo tega zdravila in se nemudoma posvetujte s svojim zdravnikom, če se razvijejo kožni izpuščaj, huda kožna reakcija ali huda rdečina in srbenje oči.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the Marketing Authorisation and any agreed subsequent updates of the RMP.
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2. dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
Do not use a double dose to make up for the forgotten dose.
Ne uporabite dvojnega odmerka, da bi nadomestili izpuščenega.
Temporary blurred vision or other visual disturbances may affect the ability to drive or use machines.
Začasno zamegljen vid ali druge motnje vida lahko vplivajo na sposobnost vožnje ali upravljanja s stroji.
If you are taking another carbonic anhydrase inhibitor (acetazolamide or dorzolamide), talk to your doctor.
Če sočasno jemljete še drug zaviralec karboanhidraze (acetazolamid ali dorzolamid), se posvetujte s svojim zdravnikom.
Patients with corneal diseases should be treated with caution.
Bolnike z boleznimi roženice je treba zdraviti previdno.
Timolol is metabolised by two pathways.
Timolol se presnavlja po dveh poteh.
If you stop using AZARGA without speaking to your doctor, the pressure in your eye will not be controlled which could lead to loss of sight.
Če ste prenehali uporabljati zdravilo AZARGA, ne da bi se posvetovali s svojim zdravnikom, vaš očesni tlak ne bo nadzorovan in lahko pride do izgube vida.
You should not use AZARGA if you are pregnant or might get pregnant, unless your doctor considers it necessary.
Zdravila AZARGA ne smete uporabljati, če ste noseči ali bi lahko zanosili, razen če vaš zdravnik meni, da je to nujno potrebno.
The safety and efficacy of AZARGA in children and adolescents aged 0 to 18 years have not yet been established.
Varnost in učinkovitost zdravila AZARGA pri otrocih in mladostnikih, starih 0 do 18 let, še nista bili dokazani.
• If you have too much acidity in your blood (a condition called hyperchloraemic acidosis).
• Če je vaša kri preveč kisla (motnja, ki ji pravimo hiperkloremična acidoza).
To reduce the systemic absorption, see section 4.2.
Glede zmanjšanja sistemske absorpcije glejte poglavje 4.2.
Studies have shown that timolol does not dialyse readily.
Študije so pokazale, da se timolol ne odstranjuje zlahka z dializo.
• Brinzolamide and timolol are absorbed systemically.
• Brinzolamid in timolol se absorbirata sistemsko.
Summary of the safety profile
Povzetek profila varnosti zdravila
, nervousness
, živčnost
Warnings and precautions Only use AZARGA for dropping in your eye(s).
Opozorila in previdnostni ukrepi Zdravilo AZARGA uporabljajte samo za vkapanje v svoje oko (oči).
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
• Preobčutljivost na učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1,
This may lead to a corneal decompensation and oedema and wearing contact lenses might increase the risk for the cornea.
To lahko vodi v dekompenzacijo ter edem roženice in bi nošenje kontaktnih leč lahko povečalo tveganje za okvaro roženice.
Alcon Cusí, S.A. Camil Fabra 58 08320 El Masnou Barcelona Spain
Alcon Cusí, S.A. Camil Fabra 58 08320 El Masnou Barcelona Španija
Children and adolescents AZARGA is not recommended for children and adolescents under 18 years.
Otroci in mladostniki Zdravilo AZARGA ni priporočljivo za otroke in mladostnike, mlajše od 18 let.
Dysgeusia (bitter or unusual taste in the mouth following instillation) was a frequently reported systemic adverse reaction associated with the use of AZARGA during clinical trials.
Disgevzija (grenek ali nenavaden okus v ustih po vkapanju zdravila) je bila pogosto prijavljen sistemski neželeni učinek, povezan z uporabo zdravila AZARGA v kliničnih preskušanjih.
AZARGA is not recommended for use in children and adolescents below 18 years due to a lack of data on safety and efficacy.
Zdravilo AZARGA ni priporočljivo za uporabo pri otrocih in mladostnikih, mlajših od 18 let, zaradi pomanjkanja podatkov o njegovi varnosti in učinkovitosti.
If you use more AZARGA than you should, rinse your eye with warm water.
Če ste uporabili večji odmerek zdravila AZARGA, kot bi smeli, sperite oko s toplo vodo.
One route yields an ethanolamine side chain on the thiadiazole ring and the other giving an ethanolic side chain on the morpholine nitrogen and a second similar side chain with a carbonyl group adjacent to the nitrogen.
Ena vodi do nastanka etanolaminske stranske verige na tiadiazolnem obroču, druga pa do nastanka etanolne stranske verige na morfolinskem dušiku in druge podobne stranske verige s karbonilno skupino sosedno od dušika.
Additional adverse reactions associated with the use of the individual components that may potentially occur with AZARGA are included in the table above.
Dodatni neželeni učinki, povezani z uporabo posameznih sestavin zdravila, ki bi se lahko pojavili tudi pri uporabi zdravila AZARGA, so vključeni v zgornjo tabelo.
Caution is recommended.
Potrebna je previdnost.
During lactation, the no adverse effect level in the offspring was 5 mg/kg/day.
Med dojenjem je odmerek brez neželenih učinkov pri mladičih znašal 5 mg/kg/dan.
If you are using other eye drop or eye ointment medicines leave at least 5 minutes between each medicine.
Če uporabljate tudi druge kapljice za oko ali mazila za oko, počakajte najmanj 5 minut med uporabo vsakega zdravila.
Do not drive or use machines until your vision is clear.
Vpliv na sposobnost upravljanja vozil in strojev Ne vozite in ne upravljajte strojev, dokler se vam vid ne zbistri.
Use in adults, including the elderly The dose is one drop of AZARGA in the conjunctival sac of the affected eye(s) twice daily.
Uporaba pri odraslih, vključno s starostniki Odmerek je ena kapljica zdravila AZARGA v veznično vrečko prizadetega očesa (oči) dvakrat na dan.
The lower systemic exposure to timolol following AZARGA administration is not clinically relevant.
Manjša sistemska izpostavljenost timololu po uporabi zdravila AZARGA ni bila klinično pomembna.
• poor blood circulation disease (such as Raynaud's disease or Raynaud's syndrome)
• bolezen z motnjami krvnega obtoka (kot je Raynaudova bolezen ali Raynaudov sindrom).
MedDRA Preferred Term (v. 18.0)
Najprimernejši izraz po klasifikaciji MedDRA (v. 18.0)
When receiving any other treatment please tell the doctor or nurse that you are taking AZARGA.
Če torej prejemate katero koli drugo zdravilo, morate zdravniku ali medicinski sestri povedati, da uporabljate tudi zdravilo AZARGA.
What AZARGA is and what it is used for
Kaj je zdravilo AZARGA in za kaj ga uporabljamo
This helps to stop AZARGA getting into the rest of the body.
Tako boste preprečili, da bi zdravilo AZARGA prišlo v druge dele telesa.
• If you have now or have had in the past respiratory problems such as asthma, severe long lasting obstructive bronchitis (severe lung condition which may cause wheezing, difficulty in breathing and/or long standing cough) or other types of breathing problems.
• Če imate ali ste imeli v preteklosti težave z dihali, na primer astmo, hud dolgotrajen obstrukcijski bronhitis (hudo stanje pljuč, ki lahko povzroči zasoplost, težko dihanje in/ali dolgotrajni kašelj) ali druge težave z dihanjem.
Following administration of AZARGA, mean Cmax of timolol was reached at 0.79 ± 0.45 hours.
Po vkapanju zdravila AZARGA je bila srednja vrednost Cmax za timolol dosežena po 0,79 ± 0,45 urah.
The combined effect of these two active substances results in additional IOP reduction compared to either compound alone.
Kombiniran učinek teh dveh zdravilnih učinkovin vodi do dodatnega znižanja očesnega tlaka v primerjavi z vsako od obeh spojin posamezno.
If overdose with AZARGA eye drops occurs, treatment should be symptomatic and supportive.
Če pride do prevelikega odmerjanja zdravila AZARGA kapljice za oko, naj bo zdravljenje simptomatsko in podporno.
Brinzolamide is not an inhibitor of cytochrome P-450 isozymes.
Brinzolamid ni zaviralec izoencimov citokroma P-450.
• Hyperchloraemic acidosis (see section 4.2).
• hiperkloremična acidoza (glejte poglavje 4.2),
Do not stop using Azarga without speaking to your doctor first.
Ne prenehajte z uporabo zdravila AZARGA, ne da bi se prej posvetovali s svojim zdravnikom.
• Ear: ringing in the ears, sensation of spinning or dizziness.
• Uho: zvonjenje v ušesih, občutek vrtenja ali omotičnosti.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from AZARGA therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja in prenehanjem/prekinitvijo zdravljenja z zdravilom AZARGA, pri čemer je treba pretehtati prednosti dojenja za otroka in prednosti zdravljenja za mater.
If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machines.
Če ima po vkapanju bolnik zamegljen vid, mora počakati, da se mu vid zbistri, preden sme voziti ali upravljati s stroji.
• After using AZARGA, press a finger into the corner of your eye, by the nose for 2 minutes
• Po uporabi zdravila AZARGA pritisnite s prstom na očesni kot ob nosu za 2 minuti (slika 3).
Instruct patients to keep the bottle tightly closed when not in use.
Bolnike poučite, da mora biti kapalni vsebnik tesno zaprt, ko ni v uporabi.
You may experience a decreased heart rate, decreased blood pressure, heart failure, difficulty breathing and your nervous system may be affected
Lahko se pojavijo zmanjšan srčni utrip, znižan krvni tlak, srčno popuščanje, težave z dihanjem in lahko je prizadet živčni sistem.
Discard 4 weeks after first opening.
Zavrzite 4 tedne po prvem odprtju.
1, memory loss
1, izguba spomina
You may find that your vision is blurred for some time just after using AZARGA.
Vaš vid bo lahko zamegljen še nekaj časa po uporabi zdravila AZARGA.
Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud's disease or Raynaud's syndrome) should be treated with caution.
Bolnike s hudimi motnjami oziroma boleznimi perifernega ožilja (npr. s hudimi oblikami Raynaudove bolezni ali z Raynaudovim sindromom) je treba zdraviti previdno.
AZARGA has minor influence on the ability to drive and use machines.
Zdravilo AZARGA ima blag vpliv na sposobnost vožnje in upravljanja strojev.
One drop in the affected eye or eyes, twice a day.
Ena kapljica v prizadeto oko ali očesi dvakrat na dan.
AZARGA is used to treat high pressure in the eyes, also called glaucoma or ocular hypertension, in adult patients that are more than 18 years of age and in whom high pressure in the eyes cannot be controlled effectively by one medicine alone.
Zdravilo AZARGA uporabljamo za zdravljenje zvišanega očesnega tlaka, imenovanega tudi glavkom ali očesna hipertenzija, pri odraslih bolnikih, ki so starejši od 18 let in pri katerih zvišanega očesnega tlaka ne moremo učinkovito nadzorovati samo z enim zdravilom.
If AZARGA is administered until delivery, the neonate should be carefully monitored during the first days of life.
Če mati uporablja zdravilo AZARGA do poroda, je treba novorojenčka skrbno spremljati v prvih nekaj dneh življenja.
If you forget to use AZARGA, continue with the next dose as planned.
Če ste pozabili uporabiti zdravilo AZARGA, nadaljujte z naslednjim odmerkom po načrtu.
There are no adequate data regarding the use of ophthalmic brinzolamide and timolol in pregnant women.
Ni zadostnih podatkov glede uporabe očesnega brinzolamida ali timolola pri nosečnicah.
AZARGA should not be used during pregnancy unless clearly necessary.
Zdravila AZARGA ne smete uporabljati med nosečnostjo, če ni nujno potrebno.
AZARGA may be used while wearing contact lenses with careful monitoring (see below under ‘Benzalkonium chloride').
Zdravilo AZARGA lahko uporabljajo nosilci kontaktnih leč s skrbnim spremljanjem (glejte spodaj pod 'Benzalkonijev klorid').
Common: punctate keratitis
Pogosti: točkasti keratitis
Eye drops, suspension
kapljice za oko, suspenzija
Brinzolamide is eliminated primarily by renal excretion (approximately 60%).
Brinzolamid se izloča predvsem preko ledvic (približno 60 %).
Since brinzolamide and its main metabolite are excreted predominantly by the kidney, AZARGA is therefore contraindicated in patients with severe renal impairment (see section 4.3).
Ker se brinzolamid in njegov glavni presnovek izločata predvsem skozi ledvice, je zdravilo AZARGA kontraindicirano pri bolnikih s hudo ledvično okvaro (glejte poglavje 4.3).
• if you have a history of atopy (a tendency to develop an allergic reaction) and severe allergic reactions you may be more sensitive to developing an allergic reaction whilst using AZARGA
• če ste imeli atopijo (nagnjenje k razvoju alergijske reakcije) in hude alergijske reakcije, boste lahko med uporabo zdravila AZARGA bolj občutljivi za razvoj alergijske reakcije in zdravljenje alergijske reakcije z adrenalinom morda ne bo tako učinkovito.
Timolol metabolism is mediated primarily by CYP2D6.
Presnova timolola poteka predvsem s pomočjo izoencima CYP2D6.
The possible role of brinzolamide on corneal endothelial function has not been investigated in patients with compromised corneas (particularly in patients with low endothelial cell count).
Morebitnega vpliva brinzolamida na delovanje roženičnega endotelija še niso raziskovali pri bolnikih z okvaro roženice (še posebej pri tistih z majhnim številom endotelijskih celic).
• General side effects: decrease in white blood cell count, decreased blood pressure, cough, blood in urine, body weakness.
• Splošni neželeni učinki: zmanjšanje števila belih krvnih celic, znižan krvni tlak, kašelj, kri v urinu, telesna oslabelost.
Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.
Spremljati morate serumske koncentracije elektrolitov (še posebej kalija) in pH vrednost krvi.